Antibody Therapeutics Xchange
East Coast 2021
May 17 & 19
Welcome to hubXchange’s virtual East Coast Antibody Therapeutics Xchange 2021, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics.
Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Antibody Strategies Driving Cell Therapies and Emerging Technologies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.
- What challenges have you faced when working with a polyclonal antibody reagent?
- How have you overcome issues in obtaining high affinity binders against large protein antigens?
- Can new technologies generate high affinity antibodies in a cost-effective way?
Director, International Business Development
Anthony has been heading the business development at Rapid Novor for nearly 4 years, merging his previous 8 years of experience in the business roles with a strong passion for biomedical research, stemming from his training in biomedical engineering. His current efforts are focused on the growth of the REpAb™and NovorIg™ platforms with pharmaceutical and biotech companies globally. His partnerships are focused on using REpAb in patients or animal models to sequence monoclonal antibodies from polyclonal sera, as well as immune system profiling using NovorIg, the team’s NGS based analysis to monitor the relative quantity of specific antibodies over time. Anthony’s a maker and in his spare time takes advantage of the Toronto HackLab to do biological research and other engineering projects.
- The vast majority of genes are alternatively spliced which one we choose
- Can we focus on pathological specific spliced targets?
- Antibody targets are often part of multimeric complexes. How can we best target them?
- Glycosylation is complex and cell specific does it alter antibody activity?
Marco obtained his PhD from University of Geneva, Switzerland and sponsored by the Glaxo Institute of Molecular Biology. His research was focused on discovery and characterization of MAP-Kinase phosphatases. Marco’s postdoctoral research was in the laboratory of Prof. JE Dixon where he discovered a highly evolutionary conserved phosphatase and contributed to developing RNAi technology as well as studying signaling in neural axon. During his industry experience, Marco led a number of programs around immuno-oncology, oncology and reproductive biology. He has a track record of successfully driving therapeutic projects resulting in best-in-class and first-in-class therapeutic molecules, starting from target selection up to lead declaration.
- Target discovery past, present and future
- How to de-risk target selection and accelerate multispecific antibody screening
- From bench side to patients, factors to be considered to bring the right biology and ensure developability
Director, Immunology Discovery Sciences
Ivan is an immunologist with more than 10 years’ experience in autoimmune diseases. Following the completion of his PhD studies he joined the Center for Neurologic Diseases at Brigham and Women’s Hospital where he studied the factors that control T cell activation and polarization by Dendritic Cells relevant for the pathologic processes involved in Multiple Sclerosis and Inflammatory Bowel Disease (IBD). Then he moved to industry and joined AbbVie Biologics, where he built experience in antibody discovery, targeted immunocytokines and conditional biologics engineering. He helped to establish the targeted and conditional biologics platform and successfully led programs into clinical development. Currently, at Pandion Therapeutics he is interested in tissue-targeted delivery of therapeutics for treatment of autoimmune diseases such as T1D, Vitiligo and IBD.
1:00 – 1:30pm
Poster Session Emerging Technologies topic Accelerating antibody discovery with a modern informatics solution
Antibody discovery is now more complex than ever. Organizations today have access to multiple antibody discovery platforms such as hybridoma and phage display, are developing an increasingly diverse set of antibody formats, and are trying to comprehensively characterize their candidates with multiple orthogonal techniques. There is need for a modern informatics solution that can map the entire process end-to-end, aggregate data across experiments and instruments quickly, and provide meaningful insights to make critical program-level decisions. This poster presentation will highlight some of the critical considerations in evaluating an informatics solution to accelerate antibody discovery.
1:40 – 2:40pm
How to select the right target or
the right combination of targets
- Available platforms for target identification
- How to identify target combinations that are unexpected and innovative
- How to validate/de-risk target combinations prior to initiating discovery campaigns
Associate Director, Discovery Research
Tommy White leads all antibody discovery efforts at Alexion where he has established in-house antibody discovery capabilities and manages the protein expression facility supporting Discovery Research. Prior to Alexion, Tommy was the second hire of the Biologics group at the Tri-Institutional Therapeutics Discovery Institute where he worked on over 50 different exploratory and therapeutic discovery programs and was key contributor on several assets licensed by external parties. He has a Ph.D. in Chemical Biology from Stevens Institute of Technology and postdoctoral training from Albert Einstein College of Medicine.